BOOM
Recent additions may not be included but will usually appear in 24 hrs or less.
| Rational | Source |
|---|---|
|
Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice. ✅
Go to Publication ✅
Microbiome research reports (Microbiome Res Rep ) Vol: 1 Issue 4 Pages: 21 Pub: 2022 Epub: 2022 Jul 19 Authors Theriot C , Thanissery R , O'Flaherty S , Barrangou R , |
|
|
Probiotics VSL#3 are effective in reversing non-alcoholic steatohepatitis in a mouse model. ✅
Go to Publication ✅
Hepatobiliary surgery and nutrition (Hepatobiliary Surg Nutr ) Vol: 9 Issue 2 Pages: 170-182 Pub: 2020 Apr Epub: Authors Jena PK , Sheng L , Li Y , Wan YY , |
|
|
Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. ✅
Go to Publication ✅
PloS one (PLoS One ) Vol: 9 Issue 9 Pages: e106503 Pub: 2014 Epub: 2014 Sep 9 Authors Distrutti E , O'Reilly JA , McDonald C , Cipriani S , Renga B , Lynch MA , Fiorucci S , |
|
|
VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer. ✅
Go to Publication ✅
Scientific reports (Sci Rep ) Vol: 3 Issue Pages: 2868 Pub: 2013 Oct 8 Epub: 2013 Oct 8 Authors Arthur JC , Gharaibeh RZ , Uronis JM , Perez-Chanona E , Sha W , Tomkovich S , Mühlbauer M , Fodor AA , Jobin C , |
|
|
VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer. ✅
Go to Publication ✅
Scientific reports (Sci Rep ) Vol: 3 Issue Pages: 2868 Pub: 2013 Oct 8 Epub: 2013 Oct 8 Authors Arthur JC , Gharaibeh RZ , Uronis JM , Perez-Chanona E , Sha W , Tomkovich S , Mühlbauer M , Fodor AA , Jobin C , |
BOOM
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance. Special thanks to Oliver Luk, B.Sc. (Biology) from BiomeSight for spot checking the coding of data from the US National Library of Medicine
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Copyright 2016-2023 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.
